Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Improved Molecular Tools Detect Influenza Virus

By LabMedica International staff writers
Posted on 08 May 2013
A set of molecular assays have been designed and evaluated for influenza viral infections that can produce results in one day without the need for additional equipment.

The molecular assays are sensitive and a good alternative for conventional diagnostic methods as they allow for the quantitative and qualitative detection of influenza virus and drug resistance mutations.

Scientists at the Erasmus University (Rotterdam, The Netherlands) designed validated and evaluated a set of real-time polymerase chain reaction (RT-PCR) assays for quantification and subtyping of human influenza A and B viruses from patient respiratory material, as well as four assays for detecting drug resistant mutations. More...


The scientific team analyzed 245 respiratory specimens from 87 patients living in Asia, Europe, and the United States of America, who were enrolled in a prospective study of influenza illness, including assessment of neuraminidase resistance. In addition, 96 prepandemic influenza A/H1N1 viruses from the epidemic of 2007-2008 were analyzed by the H275Y assay to check the robustness of the assay.

The influenza quantification assay was used to check for virus positivity and to obtain virus particle counts for all analyzed samples. Influenza A viruses were then subtyped and tested for presence of oseltamivir resistance mutations using the resistance RT-PCR assays. In total, 129 respiratory specimens tested positive for influenza A and 60 for influenza B virus. One sample tested positive for both virus types.

Although infection from H7N9, the new potential pandemic influenza strain, or H5N1, a continuing pandemic threat since 1997, can be identified by exclusion with a positive in the influenza matrix RT-PCR, but negative in RT-PCR typing. Development of rapid typing RT-PCR for these potential pandemic viruses may be useful in complementing the existing set. Within one working day, information can be obtained in parallel regarding influenza virus type or subtype, viral load, and antiviral susceptibility.

Martin Schutten, PhD, the lead author of the study said, “RT-PCR based assays have become the standard in most diagnostic laboratories worldwide in recent years. Our assays cover all currently circulating human influenza viruses and can detect major resistance mutations to oseltamivir. By introducing external quantification and internal standards, longitudinal assay performance can be monitored carefully and a virus particle count can be assigned to an analyzed sample.” The study was published in the May 2013 edition of the Journal of Molecular Diagnostics.

Related Links:
Erasmus University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.